A number of Listed Companies in the biomedical industry accept centralized research.

[industry trends of pharmaceutical Station] with the transformation of technology experience medicine such as gene detection and targeted therapy to medicine, the research and development of biomedical technology has become a hot field of scientific and technological innovation In recent years, there are many listed companies in the biopharmaceutical industry, which are concerned by institutions These include listed companies in biotechnology industry such as Kangtai biology, Guanhao biology, Shanghai Laishi and Huawei biology, as well as listed companies in pharmaceutical related industries such as medical, aojiahua and Yixintang Kangtai biology Kangtai biology received the group survey of Everbright asset management, Guotai investment trust, financial investment trust, Great Wall Fund, Huaxia Fund, Qianhai joint fund and other institutions twice last week The institutions investigated the progress of freeze-dried human rabies vaccine (human diploid cells) and the progress of 13 valent pneumococcal combined vaccine of the company in detail Kangtai bio, a listed company integrating research, development, production and sales of biological products, is one of the major manufacturers of hepatitis B vaccine in China The main business of the company is the R & D, production and sales of human vaccines The product categories cover class I and class II vaccines At present, the main products include recombinant hepatitis B vaccine (Saccharomyces cerevisiae), Haemophilus influenzae B combined vaccine, measles rubella combined live attenuated vaccine, cell-free Haemophilus influenzae B combined vaccine, 23 valent pneumococcal polysaccharide vaccine and other products Guanhao biology Guanhao biology is mainly engaged in the research and development of regenerative medical materials and regenerative medical implant devices On May 13 and May 16, it received 8 and 39 institutions to participate in the research, mainly including Shenzhen junxuan investment holding, Northeast Securities, Ping'an securities, etc the research focuses on the business situation and merger plan of Guanhao biology in the first quarter of this year Guanhao biology is based on the regenerative medicine industry, expanding the fields related to life and health, grafting the global technical resources and achievements, and continuing to layout in the fields of biomaterials, cell stem cells, pharmaceutical industry, as well as advanced medical technology and product business The core business forms a "3 + 1" pattern, namely, three business sectors of materials, cells and pharmaceutical industry and a technology incubation platform On June 26, five institutions including Dingfeng assets and Zhuque investment conducted an investigation on Shanghai Laishi Up to now, the company and its subsidiaries, Zhengzhou Laishi, Tonglu biology and Zhejiang Haikang, have 41 single plasma collection stations (including one branch station), covering 11 provinces (autonomous regions) in Guangxi, Hunan, Hainan, Shaanxi, Anhui, Guangdong, Inner Mongolia, Zhejiang, Hubei, Jiangxi and Shandong In 2018, the company's annual pulping volume is nearly 1180 tons, and the number of pulping stations and annual pulping volume are the industry leaders It is understood that Shanghai Laishi blood specializes in the production and sale of blood products, vaccines, diagnostic reagents and testing instruments, and provides testing services Its main products include human serum albumin, intravenous immunoglobulin (pH4), and human coagulation factor VIII , human prothrombin complex, human fibrinogen, freeze-dried human thrombin, freeze-dried fibrin adhesive for external use, a total of 7 varieties and 23 specifications, is one of the domestic blood product manufacturers with high comprehensive utilization rate of plasma, complete product categories and reasonable structure in the same industry, and is a well-known enterprise in the domestic blood product industry Our company released information on June 26, 2019, and received BAOYING fund research on June 25, 2019 On June 26, Wu bio announced the investigation of the organization The company said that the market in the field of allergy is very large, and with the deepening of market education in the field of allergy, there is still a huge space to continue to expand It is reported that our company has invested and established Shanghai our Stem Cell Technology Co., Ltd The newly established company will focus its resources on anti-aging and regenerative medicine through self-development and cooperation with advanced stem cell technologies and experts at home and abroad Conclusion: biomedical technology is closely related to people's health Many countries attach great importance to the development of biomedical technology and incorporate it into national important strategic deployment Under the international background of deepening scientific and technological innovation and rapid development of health medicine, China's biomedical technology has also ushered in new changes The breakthrough of basic research, innovation of biomedical technology and interdisciplinary integration in China have further enhanced the depth and breadth of application of biomedical technology.